[3-(3,4-Dimethyl-9-oxothioxanthen-2-yl)oxy-2-hydroxypropyl]-trimethylazanium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫色烯
• 英文名称: [3-(3,4-Dimethyl-9-oxothioxanthen-2-yl)oxy-2-hydroxypropyl]-trimethylazanium
• 化学式: C21H26NO3S+
• 分子量: 372.5
• InChiKey: DSPSZIUOQRESHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• DRUG COMBINATIONS TO TREAT DRUG RESISTANT TUMORS
  申请人：Kiss Zoltan

  公开号：US20080207738A1

  公开（公告）日：2008-08-28

  Embodiments of the invention provide a method and composition for treating or reducing multiple drug resistance in cancers. Embodiments of the invention also provide for a xanthene compound to inhibit multidrug resistance protein 1.

  本发明实施例提供了一种治疗或减少癌症中多药耐药的方法和组合物。本发明实施例还提供了一种黄色素化合物，用于抑制多药耐药蛋白1。
• Stable cationically crosslinkable/polymerizable dental composition with a high filler content
  申请人：Frances Jean-Marc

  公开号：US20080287562A1

  公开（公告）日：2008-11-20

  Stable and substantially filled cationic dental compositions are described which include: (1) at least one cationically reactive compound (A); (2) at least one dental filler (B); (3) optionally, at least one dispersant (C) composed of at least one organic polymer or copolymer; (4) at least one cationic photoinitiator (D); and (5) optionally, at least one photosensitizer (E). The dental filler (B) is treated with at least one organosilicon coupling agent (F), and at least one compound (G). The organosilicon coupling agent (F) has at least one reactive function (rfA) directly linked to a silicon atom forming after activation of a chemical bond with the dental filler, and at least one reactive function (rfB) not directly linked to a silicon atom, forming after activation, a chemical bond with a reactive function (rfC) of the compound (G).

  本文介绍了一种稳定且填充充足的阳离子牙科组合物，其中包括：（1）至少一种阳离子反应化合物（A）；（2）至少一种牙科填充物（B）；（3）可选地，至少一种由至少一种有机聚合物或共聚物组成的分散剂（C）；（4）至少一种阳离子光引发剂（D）；以及（5）可选地，至少一种光敏剂（E）。牙科填充物（B）经过至少一种有机硅偶联剂（F）处理，以及至少一种化合物（G）。有机硅偶联剂（F）具有至少一个反应功能（rfA），直接连接到形成化学键的硅原子上，与牙科填充物发生作用；以及至少一个反应功能（rfB），在激活后不直接连接到硅原子，与化合物（G）的反应功能（rfC）形成化学键。
• COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH
  申请人：Kiss Zoltan

  公开号：US20100022617A1

  公开（公告）日：2010-01-28

  A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.

  一类含有三烷基铵基团的化合物已被合成和表征为抗癌化合物。该类化合物的代表物N,N-二乙基-N-甲基-2-[(9-氧代-9H-噻吩并[2,3-f]苯并-2-基)甲氧基]乙胺碘化物（CCDTHT）在各种肿瘤模型中表现出降低肿瘤体积、增强其他化疗药物（包括顺铂）的作用、减少化疗所致体重丢失和增加与顺铂一起治疗的动物的生存率等效应。当与人类蛋白质胎盘碱性磷酸酶一起给动物治疗时，CCDTHT对肿瘤体积、体重和生存率的影响更大。这些含有三烷基铵基团和碱性磷酸酶的化合物，特别是它们相互之间和与其他治疗方法相结合，可能被用于治疗癌症和其他细胞增殖性疾病。
• COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH
  申请人：Kiss Zoltan

  公开号：US20070060634A1

  公开（公告）日：2007-03-15

  A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.

  一类常见的化合物，通常含有三烷基铵基团，已被合成并作为抗癌化合物进行了表征。该类化合物的代表物是N，N-二乙基-N-甲基-2-[(9-氧代-9H-噻二苯并-2-基)甲氧基]乙胺碘化物（CCDTHT），在各种肿瘤模型中显示出降低肿瘤体积、增强其他化疗药物（包括顺铂）的效果、减少化疗引起的体重损失以及增加共同接受有毒量顺铂的动物的生存率。当与人类蛋白质胎盘碱性磷酸酶一起给动物施用时，CCDTHT对肿瘤体积、体重和生存率的影响更大。这些含有三烷基铵基团和碱性磷酸酶的化合物，特别是与彼此和其他治疗方法结合使用时，可用于治疗癌症和其他细胞增殖性疾病。
• Printing method, method for preparing overprint, method for processing laminate, light-emitting diode curable coating composition, and light-emitting diode curable ink composition
  申请人：Fujifilm Corporation

  公开号：EP2388146A2

  公开（公告）日：2011-11-23

  Provided is a light-emitting diode curable ink composition or coating composition having a practical curing sensitivity by irradiating ultraviolet rays having a peak wavelength at 375 to 395 nm by a light-emitting diode, providing a cured matter having excellent non-tackiness, and also having excellent hue without unnecessary absorption in a visible region. A light-emitting diode curable coating composition including (component A) compound represented by the formula (I), (component B) a photopolymerization initiator, and (component C) an ethylenically unsaturated compound, and a light-emitting diode curable ink composition including (component A) a compound represented by the formula (I), (component B) a photopolymerization initiator, (component C) an ethylenically unsaturated compound, and (component D) a colorant.

  本发明提供了一种发光二极管可固化油墨组合物或涂料组合物，该组合物通过发光二极管照射峰值波长为 375 至 395 纳米的紫外线，具有实用的固化灵敏度，固化物具有极佳的非粘性，同时还具有极佳的色调，在可见光区域没有不必要的吸收。 一种发光二极管可固化涂料组合物，包括（A 组分）式（I）所代表的化合物、（B 组分）光聚合引发剂和（C 组分）乙烯基不饱和化合物，以及一种发光二极管可固化油墨组合物，包括（A 组分）式（I）所代表的化合物、（B 组分）光聚合引发剂、（C 组分）乙烯基不饱和化合物和（D 组分）着色剂。